Related Experiment Video

Updated: Jan 21, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

355

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort

Irena Tan1, Thomas E Stinchcombe2,3, Neal E Ready2,3

  • 1Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA.

Translational Lung Cancer Research
|August 2, 2019
PubMed
Abstract

Insights

Outcomes for non-small cell lung cancer (NSCLC) with BRAF mutations treated with chemotherapy or immunotherapy are described. This small study found no clear benefit of immunotherapy over chemotherapy in this patient group.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Limited data exists on therapeutic outcomes for non-small cell lung cancer (NSCLC) patients with BRAF mutations.
  • BRAF mutations are an important target in various cancers, but their impact on NSCLC treatment response is not fully understood.

Purpose of the Study:

  • To evaluate the clinical response to immunotherapy and chemotherapy in patients with metastatic NSCLC harboring BRAF mutations.
  • To describe therapeutic outcomes in this specific patient population.

Main Methods:

  • A retrospective cohort study was conducted involving 31 patients with metastatic NSCLC and BRAF mutations.
  • Tumor samples were analyzed using next-generation sequencing to identify BRAF mutations.
  • Patients received either first-line chemotherapy or immunotherapy.

Main Results:

  • Of the 31 patients, 45.2% had a BRAF V600E mutation and 54.8% had a non-V600E mutation.
  • Median progression-free survival (PFS) for patients receiving first-line chemotherapy was 6.4 months.
  • Overall survival (OS) did not significantly differ between patients with different BRAF mutation types or between those treated with or without targeted BRAF inhibitors. Immunotherapy did not show improved clinical activity.

Conclusions:

  • Therapeutic outcomes for metastatic NSCLC patients with BRAF mutations treated with chemotherapy or immunotherapy were described.
  • Despite the small sample size, survival data did not indicate superior clinical activity for immunotherapy in this population.
  • Further research with larger cohorts is needed to fully elucidate optimal treatment strategies.
Keywords:
ImmunotherapyV600Eamplificationchemotherapyretrospective cohort study

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.5K
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.5K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
43.8K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.1K
Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.3K